Trevi Therapeutics, Inc. (TRVI)
Develops a medicine to reduce chronic cough in lung disease patients.
$18.43+0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+151.4%
The outlook
TRVI is trading near its 52-week highs with strong analyst support—the consensus sits at Strong Buy, and the average price target implies roughly 42% upside from current levels. The stock is trading above both its 50- and 200-day moving averages, reflecting a sustained uptrend. Analyst coverage is solid at 11 firms.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 11 analysts
Price trendAbove its 50- & 200-day averages
52-week range87% of the way from its 52-week low to high
Price targetAvg target +42% vs current price
Analyst price target
~12-month · 11 analysts$26.18average target+42.1% vs now
Now $18.43
Low $20.00High $36.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.62B
52-wk high
$20.22
52-wk low
$6.55
50-day avg
$16.07
200-day avg
$12.99
Trailing P/E
—